| Year |
Citation |
Score |
| 2020 |
Nestor LJ, Suckling J, Ersche KD, Murphy A, McGonigle J, Orban C, Paterson LM, Reed L, Taylor E, Flechais R, Smith D, Bullmore ET, Elliott R, Deakin B, Rabiner I, ... ... Nutt DJ, et al. Disturbances across whole brain networks during reward anticipation in an abstinent addiction population. Neuroimage. Clinical. 27: 102297. PMID 32505119 DOI: 10.1016/J.Nicl.2020.102297 |
0.303 |
|
| 2020 |
Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic Psychiatry's Brave New World. Cell. 181: 24-28. PMID 32243793 DOI: 10.1016/J.Cell.2020.03.020 |
0.325 |
|
| 2019 |
Erritzoe D, Ashok AH, Searle GE, Colasanti A, Turton S, Lewis Y, Huiban M, Moz S, Passchier J, Saleem A, Beaver J, Lingford-Hughes A, Nutt DJ, Howes OD, Gunn RN, et al. Serotonin release measured in the human brain: a PET study with [C]CIMBI-36 and d-amphetamine challenge. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31715617 DOI: 10.1038/S41386-019-0567-5 |
0.3 |
|
| 2019 |
Jefsen O, Højgaard K, Christiansen SL, Elfving B, Nutt DJ, Wegener G, Müller HK. Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta Neuropsychiatrica. 1-7. PMID 31106729 DOI: 10.1017/Neu.2019.15 |
0.301 |
|
| 2019 |
Sessa B, Higbed L, Nutt D. A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Frontiers in Psychiatry. 10: 138. PMID 30949077 DOI: 10.3389/Fpsyt.2019.00138 |
0.308 |
|
| 2019 |
Nutt D. Psychedelic drugs-a new era in psychiatry? . Dialogues in Clinical Neuroscience. 21: 139-147. DOI: 10.31887/Dcns.2019.21.2/Dnutt |
0.339 |
|
| 2018 |
Nestor LJ, Paterson LM, Murphy A, McGonigle J, Orban C, Reed L, Taylor E, Flechais R, Smith D, Bullmore ET, Ersche KD, Suckling J, Elliott R, Deakin B, Rabiner I, ... ... Nutt DJ, et al. Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and poly-substance dependent individuals. The European Journal of Neuroscience. PMID 30402987 DOI: 10.1111/Ejn.14262 |
0.33 |
|
| 2018 |
Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, Husbands SM, Rabiner EIA, Gunn RN, Murphy PS, Parker CA, Nutt DJ. Evaluation ofC-BU99008, a positron emission tomography ligand for the Imidazolinebinding site in human brain. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29523627 DOI: 10.2967/Jnumed.118.208009 |
0.304 |
|
| 2017 |
Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. PMID 29284138 DOI: 10.1016/J.Neuropharm.2017.12.040 |
0.326 |
|
| 2017 |
Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports. 7: 13187. PMID 29030624 DOI: 10.1038/S41598-017-13282-7 |
0.323 |
|
| 2017 |
Law FD, Diaper AM, Melichar JK, Coulton S, Nutt DJ, Myles JS. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals. Journal of Psychopharmacology (Oxford, England). 269881117711710. PMID 28631527 DOI: 10.1177/0269881117711710 |
0.311 |
|
| 2017 |
Savulich G, Riccelli R, Passamonti L, Correia M, Deakin JF, Elliott R, Flechais RS, Lingford-Hughes AR, McGonigle J, Murphy A, Nutt DJ, Orban C, Paterson LM, Reed LJ, Smith DG, et al. Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery. Translational Psychiatry. 7: e1054. PMID 28267152 DOI: 10.1038/Tp.2017.34 |
0.301 |
|
| 2017 |
Morris LS, Baek K, Tait R, Elliott R, Ersche KD, Flechais R, McGonigle J, Murphy A, Nestor LJ, Orban C, Passetti F, Paterson LM, Rabiner I, Reed L, Smith D, ... ... Nutt DJ, et al. Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. Addiction Biology. PMID 28247526 DOI: 10.1111/Adb.12503 |
0.33 |
|
| 2017 |
Badiani A, Berridge KC, Heilig M, Nutt DJ, Robinson TE. Addiction research and theory: a commentary on the Surgeon General's Report on alcohol, drugs, and health. Addiction Biology. PMID 28224686 DOI: 10.1111/Adb.12497 |
0.345 |
|
| 2017 |
Walpola IC, Nest T, Roseman L, Erritzoe D, Feilding A, Nutt DJ, Carhart-Harris RL. Altered Insula Connectivity Under MDMA. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28195139 DOI: 10.1038/Npp.2017.35 |
0.333 |
|
| 2017 |
Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, ... ... Nutt DJ, et al. Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28042871 DOI: 10.1038/Npp.2016.289 |
0.357 |
|
| 2017 |
Morgan C, McAndrew A, Stevens T, Nutt D, Lawn W. Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use Current Opinion in Behavioral Sciences. 13: 71-76. DOI: 10.1016/J.Cobeha.2016.10.009 |
0.325 |
|
| 2016 |
Nutt D, Stahl S, Blier P, Drago F, Zohar J, Wilson S. Inverse agonists - What do they mean for psychiatry? European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 27955830 DOI: 10.1016/J.Euroneuro.2016.11.013 |
0.319 |
|
| 2016 |
Mick I, Ramos AC, Myers J, Stokes PR, Chandrasekera S, Erritzoe D, Mendez MA, Gunn RN, Rabiner EA, Searle GE, Galduróz JC, Waldman AD, Bowden-Jones H, Clark L, Nutt DJ, et al. Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity. Addiction Biology. PMID 27739164 DOI: 10.1111/Adb.12457 |
0.339 |
|
| 2016 |
McGonigle J, Murphy A, Paterson LM, Reed LJ, Nestor L, Nash J, Elliott R, Ersche KD, Flechais RS, Newbould R, Orban C, Smith DG, Taylor EM, Waldman AD, Robbins TW, ... ... Nutt DJ, et al. The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description. Journal of Psychopharmacology (Oxford, England). PMID 27703042 DOI: 10.1177/0269881116668592 |
0.33 |
|
| 2016 |
Shimshoni JA, Winkler I, Golan E, Nutt D. Neurochemical binding profiles of novel indole and benzofuran MDMA analogues. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 27650729 DOI: 10.1007/S00210-016-1297-4 |
0.301 |
|
| 2016 |
Nestor LJ, Murphy A, McGonigle J, Orban C, Reed L, Taylor E, Flechais R, Paterson LM, Smith D, Bullmore ET, Ersche KD, Suckling J, Tait R, Elliott R, Deakin B, ... ... Nutt DJ, et al. Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task. Addiction Biology. PMID 27600363 DOI: 10.1111/Adb.12444 |
0.354 |
|
| 2016 |
Carhart-Harris RL, Nutt DJ. Question-based Drug Development for psilocybin - Authors' reply. The Lancet. Psychiatry. 3: 807. PMID 27568266 DOI: 10.1016/S2215-0366(16)30217-6 |
0.302 |
|
| 2016 |
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet. Psychiatry. PMID 27210031 DOI: 10.1016/S2215-0366(16)30065-7 |
0.305 |
|
| 2016 |
Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E, Williams T, Bolstridge M, Feilding A, Nutt DJ, et al. Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Current Biology : Cb. PMID 27085214 DOI: 10.1016/J.Cub.2016.02.010 |
0.343 |
|
| 2016 |
Kaelen M, Roseman L, Kahan J, Santos-Ribeiro A, Orban C, Lorenz R, Barrett FS, Bolstridge M, Williams T, Williams L, Wall MB, Feilding A, Muthukumaraswamy S, Nutt DJ, Carhart-Harris R. LSD modulates music-induced imagery via changes in parahippocampal connectivity. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 27084302 DOI: 10.1016/J.Euroneuro.2016.03.018 |
0.319 |
|
| 2016 |
Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, ... ... Nutt DJ, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences of the United States of America. PMID 27071089 DOI: 10.1073/Pnas.1518377113 |
0.318 |
|
| 2016 |
Speth J, Speth C, Kaelen M, Schloerscheidt AM, Feilding A, Nutt DJ, Carhart-Harris RL. Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. Journal of Psychopharmacology (Oxford, England). 30: 344-53. PMID 26979587 DOI: 10.1177/0269881116628430 |
0.303 |
|
| 2016 |
Taylor EM, Murphy A, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, McGonigle J, Metastasio A, Nestor L, Orban C, Passetti F, Paterson L, Smith D, Suckling J, Tait R, ... ... Nutt DJ, et al. Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach. Psychopharmacology. PMID 26911382 DOI: 10.1007/S00213-016-4245-6 |
0.303 |
|
| 2015 |
Maron E, Wall M, Norbury R, Godlewska B, Terbeck S, Cowen P, Matthews P, Nutt DJ. Effect of short-term escitalopram treatment on neural activation during emotional processing. Journal of Psychopharmacology (Oxford, England). PMID 26645207 DOI: 10.1177/0269881115620462 |
0.306 |
|
| 2015 |
Mick I, Myers J, Ramos AC, Stokes PR, Erritzoe D, Colasanti A, Gunn RN, Rabiner EA, Searle GE, Waldman AD, Parkin MC, Brailsford AD, Galduróz JC, Bowden-Jones H, Clark L, ... Nutt DJ, et al. Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26552847 DOI: 10.1038/Npp.2015.340 |
0.327 |
|
| 2015 |
Korpi ER, den Hollander B, Farooq U, Vashchinkina E, Rajkumar R, Nutt DJ, Hyytiä P, Dawe GS. Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. Pharmacological Reviews. 67: 872-1004. PMID 26403687 DOI: 10.1124/Pr.115.010967 |
0.374 |
|
| 2015 |
Paterson LM, Flechais RS, Murphy A, Reed LJ, Abbott S, Boyapati V, Elliott R, Erritzoe D, Ersche KD, Faluyi Y, Faravelli L, Fernandez-Egea E, Kalk NJ, Kuchibatla SS, McGonigle J, ... ... Nutt DJ, et al. The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. Journal of Psychopharmacology (Oxford, England). PMID 26246443 DOI: 10.1177/0269881115596155 |
0.37 |
|
| 2015 |
Lebedev AV, Lövdén M, Rosenthal G, Feilding A, Nutt DJ, Carhart-Harris RL. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Human Brain Mapping. 36: 3137-53. PMID 26010878 DOI: 10.1002/Hbm.22833 |
0.314 |
|
| 2015 |
Aubin HJ, Reimer J, Nutt DJ, Bladström A, Torup L, François C, Chick J. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. European Addiction Research. 21: 160-8. PMID 25832297 DOI: 10.1159/000371547 |
0.304 |
|
| 2015 |
Stuart SA, Butler P, Munafò MR, Nutt DJ, Robinson ES. Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 2165-74. PMID 25740288 DOI: 10.1038/Npp.2015.59 |
0.33 |
|
| 2015 |
Sessa B, Nutt D. Making a medicine out of MDMA. The British Journal of Psychiatry : the Journal of Mental Science. 206: 4-6. PMID 25561485 DOI: 10.1192/Bjp.Bp.114.152751 |
0.309 |
|
| 2015 |
Nutt DJ. Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective. Journal of Psychopharmacology (Oxford, England). 29: 43-9. PMID 25389219 DOI: 10.1177/0269881114555248 |
0.358 |
|
| 2015 |
Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ. LSD enhances suggestibility in healthy volunteers Psychopharmacology. 232: 785-794. PMID 25242255 DOI: 10.1007/S00213-014-3714-Z |
0.302 |
|
| 2014 |
Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Frontiers in Human Neuroscience. 8: 204. PMID 24904346 DOI: 10.3389/Fnhum.2014.00204 |
0.319 |
|
| 2014 |
Crawford AA, Lewis S, Nutt D, Peters TJ, Cowen P, O'Donovan MC, Wiles N, Lewis G. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology. 231: 2921-31. PMID 24525810 DOI: 10.1007/S00213-014-3467-8 |
0.301 |
|
| 2013 |
Argyropoulos SV, Nutt DJ. Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? Journal of Psychopharmacology (Oxford, England). 27: 869-77. PMID 23904408 DOI: 10.1177/0269881113494104 |
0.303 |
|
| 2013 |
Carhart-Harris RL, Brugger S, Nutt DJ, Stone JM. Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. Journal of Psychopharmacology (Oxford, England). 27: 771-8. PMID 23784738 DOI: 10.1177/0269881113494107 |
0.312 |
|
| 2013 |
Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews. Neuroscience. 14: 577-85. PMID 23756634 DOI: 10.1038/Nrn3530 |
0.315 |
|
| 2013 |
Stuart SA, Butler P, Munafò MR, Nutt DJ, Robinson ES. A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1625-35. PMID 23503126 DOI: 10.1038/Npp.2013.69 |
0.327 |
|
| 2013 |
Tõru I, Maron E, Raag M, Vasar V, Nutt DJ, Shlik J. The effect of 6-week treatment with escitalopram on CCK-4 challenge: A placebo-controlled study in CCK-4-sensitive healthy volunteers European Neuropsychopharmacology. 23: 645-652. PMID 22939006 DOI: 10.1016/J.Euroneuro.2012.08.011 |
0.315 |
|
| 2013 |
Mendez MA, Horder J, Myers J, Coghlan S, Stokes P, Erritzoe D, Howes O, Lingford-Hughes A, Murphy D, Nutt D. The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology. 68: 195-201. PMID 22546616 DOI: 10.1016/J.Neuropharm.2012.04.008 |
0.302 |
|
| 2012 |
Nutt DJ, Lingford-Hughes A, Chick J. Through a glass darkly: Can we improve clarity about mechanism and aims of medications in drug and alcohol treatments? Journal of Psychopharmacology. 26: 199-204. PMID 22287478 DOI: 10.1177/0269881111410899 |
0.304 |
|
| 2012 |
Schlaepfer TE, Agren H, Monteleone P, Gasto C, Pitchot W, Rouillon F, Nutt DJ, Kasper S. The hidden third: improving outcome in treatment-resistant depression. Journal of Psychopharmacology (Oxford, England). 26: 587-602. PMID 22236505 DOI: 10.1177/0269881111431748 |
0.309 |
|
| 2012 |
Nutt D. JS01-01 - New classification of psychiatric medications: report of work in progress European Psychiatry. 27: 1. DOI: 10.1016/S0924-9338(12)74098-1 |
0.329 |
|
| 2011 |
Bailey JE, Dawson GR, Dourish CT, Nutt DJ. Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). Journal of Psychopharmacology (Oxford, England). 25: 1192-8. PMID 21994314 DOI: 10.1177/0269881111408455 |
0.307 |
|
| 2011 |
Bailey JE, Papadopoulos A, Diaper A, Phillips S, Schmidt M, van der Ark P, Dourish CT, Dawson GR, Nutt DJ. Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. Journal of Psychopharmacology (Oxford, England). 25: 1199-206. PMID 21555331 DOI: 10.1177/0269881111400650 |
0.342 |
|
| 2011 |
Kalk NJ, Nutt DJ, Lingford-Hughes AR. The Role of Central Noradrenergic Dysregulation in Anxiety Disorders: Evidence From Clinical Studies Journal of Psychopharmacology. 25: 3-16. PMID 20530586 DOI: 10.1177/0269881110367448 |
0.303 |
|
| 2011 |
Corrigan FM, Fisher JJ, Nutt DJ. Autonomic dysregulation and the Window of Tolerance model of the effects of complex emotional trauma Journal of Psychopharmacology. 25: 17-25. PMID 20093318 DOI: 10.1177/0269881109354930 |
0.311 |
|
| 2011 |
Hood SD, Melichar JK, Taylor LG, Kalk N, Edwards TR, Hince DA, Lenox-Smith A, Lingford-Hughes AR, Nutt DJ. Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. Journal of Psychopharmacology (Oxford, England). 25: 78-86. PMID 20093317 DOI: 10.1177/0269881109359099 |
0.321 |
|
| 2010 |
Nutt DJ. Antagonist—agonist combinations as therapies for heroin addiction: back to the future? Journal of Psychopharmacology. 24: 141-145. PMID 20145102 DOI: 10.1177/0269881109356129 |
0.324 |
|
| 2010 |
Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics: Journal of Psychopharmacology. 24: 1601-1612. PMID 19942638 DOI: 10.1177/0269881109106927 |
0.335 |
|
| 2010 |
Hood SD, Potokar JP, Davies SJ, Hince DA, Morris K, Seddon KM, Nutt DJ, Argyropoulos SV. Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. Journal of Psychopharmacology (Oxford, England). 24: 709-16. PMID 18838500 DOI: 10.1177/0269881108098144 |
0.312 |
|
| 2010 |
Davidson JR, Zhang W, Connor KM, Ji J, Jobson K, Lecrubier Y, McFarlane AC, Newport DJ, Nutt DJ, Osser DN, Stein DJ, Stowe ZN, Tajima O, Versiani M. A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). Journal of Psychopharmacology (Oxford, England). 24: 3-26. PMID 18832431 DOI: 10.1177/0269881108096505 |
0.312 |
|
| 2009 |
Durant C, Christmas D, Nutt D. The pharmacology of anxiety. Current Topics in Behavioral Neurosciences. 2: 303-330. PMID 21309115 DOI: 10.1007/7854_2009_8 |
0.31 |
|
| 2009 |
Nutt D. Equasy-- an overlooked addiction with implications for the current debate on drug harms. Journal of Psychopharmacology. 23: 3-5. PMID 19158127 DOI: 10.1177/0269881108099672 |
0.305 |
|
| 2009 |
Nutt D, Mandel F, Baldinetti F. Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model. Journal of Psychopharmacology (Oxford, England). 23: 867-73. PMID 18635690 DOI: 10.1177/0269881108094722 |
0.301 |
|
| 2009 |
Bailey JE, Papadopoulos A, Seddon K, Nutt DJ. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. Journal of Psychopharmacology (Oxford, England). 23: 117-22. PMID 18562427 DOI: 10.1177/0269881108089603 |
0.339 |
|
| 2009 |
Nutt D, Lingford-Hughes A. Addiction: the clinical interface. British Journal of Pharmacology. 154: 397-405. PMID 18414399 DOI: 10.1038/Bjp.2008.101 |
0.334 |
|
| 2009 |
Nutt D. S03-01 Introducing the pharmacology behind treatments to understand treatment challenges European Psychiatry. 24: 1-1. DOI: 10.1016/S0924-9338(09)70250-0 |
0.314 |
|
| 2009 |
Davies S, Nash J, Nutt D. Management of panic disorder in the primary-care setting Prescriber. 20: 17-26. DOI: 10.1002/Psb.500 |
0.333 |
|
| 2008 |
Christmas D, Hood S, Nutt D. Potential novel anxiolytic drugs. Current Pharmaceutical Design. 14: 3534-3546. PMID 19075730 DOI: 10.2174/138161208786848775 |
0.337 |
|
| 2008 |
Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, Grasby PM, Nutt DJ. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study British Journal of Psychiatry. 193: 229-234. PMID 18757983 DOI: 10.1192/Bjp.Bp.107.041186 |
0.328 |
|
| 2008 |
Thomas L, Mulligan J, Mason V, Tallon D, Wiles N, Cowen P, Nutt D, O'Donovan M, Sharp D, Peters T, Lewis G. GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. Trials. 9: 29. PMID 18498636 DOI: 10.1186/1745-6215-9-29 |
0.308 |
|
| 2008 |
Bailey JE, Nutt DJ. GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety? Pharmacology, Biochemistry, and Behavior. 90: 51-7. PMID 18485466 DOI: 10.1016/J.Pbb.2008.04.002 |
0.309 |
|
| 2008 |
Nutt DJ, Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy Journal of Psychopharmacology. 22: 3-6. PMID 18187527 DOI: 10.1177/0269881107086283 |
0.318 |
|
| 2007 |
Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lépine JP, Möller HJ, Nutt DJ, Rouillon F, Schatzberg AF, Thase ME. Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology. 22: 323-9. PMID 17917550 DOI: 10.1097/Yic.0B013E3282Eff7E0 |
0.308 |
|
| 2007 |
Bailey JE, Papadopoulos A, Lingford-Hughes A, Nutt DJ. D-Cycloserine and performance under different states of anxiety in healthy volunteers. Psychopharmacology. 193: 579-85. PMID 17510758 DOI: 10.1007/S00213-007-0817-9 |
0.311 |
|
| 2007 |
Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 369: 1047-53. PMID 17382831 DOI: 10.1016/S0140-6736(07)60464-4 |
0.524 |
|
| 2007 |
Nutt DJ, Stein DJ. Understanding the neurobiology of comorbidity in anxiety disorders. Cns Spectrums. 11: 13-20. PMID 17008826 DOI: 10.1017/S1092852900025803 |
0.33 |
|
| 2007 |
Nutt D, King L, Saulsbury W, Blakemore C. Assessing drug-related harm - Authors' reply Lancet. 369: 1857. DOI: 10.1016/S0140-6736(07)60843-5 |
0.501 |
|
| 2007 |
Seddon K, Nutt D. Pharmacological treatment of bipolar disorder Psychiatry Mmc. 6: 305-308. DOI: 10.1016/J.Mppsy.2007.04.006 |
0.305 |
|
| 2007 |
Seddon K, Nutt D. Pharmacological treatment of panic disorder Psychiatry Mmc. 6: 198-203. DOI: 10.1016/J.Mppsy.2007.02.005 |
0.303 |
|
| 2006 |
Nutt D, Argyropoulos S, Hood S, Potokar J. Generalized anxiety disorder: A comorbid disease. European Neuropsychopharmacology. 16. PMID 16737802 DOI: 10.1016/J.Euroneuro.2006.04.003 |
0.324 |
|
| 2006 |
Nutt D. GABAA receptors: subtypes, regional distribution, and function. Journal of Clinical Sleep Medicine : Jcsm : Official Publication of the American Academy of Sleep Medicine. 2. DOI: 10.5664/Jcsm.26525 |
0.315 |
|
| 2006 |
Hood SD, Argyropoulos SV, Davies SJC, Hince DA, Bell CJ, Nutt DJ, Potokar J. P.4.e.005 The effect of acute tryptophan depletion on challenge induced anxiety in anxiety disorder patients is independent of a history of depression European Neuropsychopharmacology. 16. DOI: 10.1016/S0924-977X(06)70627-7 |
0.301 |
|
| 2005 |
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology (Oxford, England). 19: 567-96. PMID 16272179 DOI: 10.1177/0269881105059253 |
0.3 |
|
| 2005 |
Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. Cns Spectrums. 10: 49-56. PMID 15618947 DOI: 10.1017/S1092852900009901 |
0.33 |
|
| 2004 |
Nutt D. Anxiety and depression: individual entities or two sides of the same coin? International Journal of Psychiatry in Clinical Practice. 8: 19-24. PMID 24930685 DOI: 10.1080/13651500410005513 |
0.317 |
|
| 2004 |
Argyropoulos SV, Hood SD, Adrover M, Bell CJ, Rich AS, Nash JR, Rich NC, Witchel HJ, Nutt DJ. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biological Psychiatry. 56: 503-9. PMID 15450786 DOI: 10.1016/J.Biopsych.2004.07.006 |
0.321 |
|
| 2004 |
Davies SJ, Jackson PR, Potokar J, Nutt DJ. Treatment of anxiety and depressive disorders in patients with cardiovascular disease. Bmj (Clinical Research Ed.). 328: 939-43. PMID 15087342 DOI: 10.1136/Bmj.328.7445.939 |
0.302 |
|
| 2004 |
Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, Nutt DJ, Okasha A, Swinson RP. WCA recommendations for the long-term treatment of panic disorder. Cns Spectrums. 8: 17-30. PMID 14767395 DOI: 10.1017/S109285290000691X |
0.322 |
|
| 2004 |
Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, Okasha A, Swinson RP, Zohar J. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. Cns Spectrums. 8: 7-16. PMID 14767394 DOI: 10.1017/S1092852900006908 |
0.309 |
|
| 2004 |
Slattery DA, Hudson AL, Nutt DJ. Invited review: the evolution of antidepressant mechanisms. Fundamental & Clinical Pharmacology. 18: 1-21. PMID 14748749 DOI: 10.1111/J.1472-8206.2004.00195.X |
0.305 |
|
| 2004 |
Nutt D, Lingford-Hughes A. Key concepts in psychopharmacology Psychiatry Mmc. 3: 263-267. DOI: 10.1383/Psyt.3.7.1.42877 |
0.311 |
|
| 2004 |
Nash J, Nutt DJ. Psychopharmacology of anxiety Psychiatry Mmc. 3: 143-148. DOI: 10.1383/psyt.3.4.11.32907 |
0.339 |
|
| 2003 |
Nutt DJ. Death and Dependence: Current Controversies over the Selective Serotonin Reuptake Inhibitors: Journal of Psychopharmacology. 17: 355-364. PMID 14870946 DOI: 10.1177/0269881103174019 |
0.311 |
|
| 2003 |
Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP. WCA recommendations for the long-term treatment of generalized anxiety disorder. Cns Spectrums. 8: 53-61. PMID 14767398 DOI: 10.1017/S1092852900006945 |
0.313 |
|
| 2003 |
Nutt D, Lingford-Hughes A, Daglish M. Future directions in substance dependence research. Journal of Neural Transmission-Supplement. 95-103. PMID 12830931 DOI: 10.1007/978-3-7091-6020-6_6 |
0.33 |
|
| 2003 |
Lingford-Hughes A, Nutt D. Neurobiology of addiction and implications for treatment British Journal of Psychiatry. 182: 97-100. PMID 12562734 DOI: 10.1192/Bjp.182.2.97 |
0.329 |
|
| 2003 |
Hood SD, Argyropoulos SV, Nutt DJ. New directions in the treatment of anxiety disorders Expert Opinion On Therapeutic Patents. 13: 401-423. DOI: 10.1517/13543776.13.4.401 |
0.312 |
|
| 2002 |
Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU. Generalized anxiety disorder: comorbidity, comparative biology and treatment. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 5: 315-25. PMID 12466031 DOI: 10.1017/S1461145702003048 |
0.311 |
|
| 2002 |
Nutt DJ. The neuropharmacology of serotonin and noradrenaline in depression. International Clinical Psychopharmacology. 17. PMID 12369606 DOI: 10.1097/00004850-200206001-00002 |
0.334 |
|
| 2002 |
Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S, Rich A, Nutt DJ. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine Journal of Psychopharmacology. 16: 5-14. PMID 11949771 DOI: 10.1177/026988110201600116 |
0.336 |
|
| 2001 |
Argyropoulos SV, Bell CJ, Nutt DJ. Brain function in social anxiety disorder. The Psychiatric Clinics of North America. 24: 707-22. PMID 11723629 DOI: 10.1016/S0193-953X(05)70259-8 |
0.324 |
|
| 2001 |
Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D'Orlando KJ, Gammans RE, Nutt DJ. Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. Journal of Psychopharmacology. 15: 205-208. PMID 11565630 DOI: 10.1177/026988110101500312 |
0.307 |
|
| 2001 |
Bell C, Abrams J, Nutt D. Tryptophan depletion and its implications for psychiatry. British Journal of Psychiatry. 178: 399-405. PMID 11331552 DOI: 10.1192/Bjp.178.5.399 |
0.333 |
|
| 2000 |
Argyropoulos SV, Sandford JJ, Nutt DJ. The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety. Pharmacology & Therapeutics. 88: 213-227. PMID 11337026 DOI: 10.1016/S0163-7258(00)00083-8 |
0.329 |
|
| 2000 |
Sandford JJ, Argyropoulos SV, Nutt DJ. Associate editor: A.E. D.J.K. BalfourThe psychobiology of anxiolytic drugs: Part 1: Basic neurobiology Pharmacology & Therapeutics. 88. PMID 11337025 DOI: 10.1016/S0163-7258(00)00082-6 |
0.306 |
|
| 2000 |
Argyropoulos SV, Nutt DJ. Substance P antagonists: novel agents in the treatment of depression Expert Opinion On Investigational Drugs. 9: 1871-1875. PMID 11060783 DOI: 10.1517/13543784.9.8.1871 |
0.317 |
|
| 2000 |
Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines Journal of Psychopharmacology. 14: 3-20. PMID 10757248 DOI: 10.1177/026988110001400101 |
0.312 |
|
| 2000 |
Hood SD, Argyropoulos SV, Nutt DJ. Agents in Development for Anxiety Disorders Cns Drugs. 13: 421-431. DOI: 10.2165/00023210-200013060-00004 |
0.34 |
|
| 2000 |
Sargent P, Nash J, Hood S, Rabiner E, Messa C, Cowen P, Nutt D, Grasby P. 5-HT1A receptor binding in panic disorder; comparison with depressive disorder and healthy volunteers using PET and [11C]WAY-100635 Neuroimage. 11. DOI: 10.1016/S1053-8119(00)91122-4 |
0.31 |
|
| 1999 |
Nutt DJ, Forshall S, Bell C, Rich A, Sandford J, Nash J, Argyropoulos S. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders European Neuropsychopharmacology. 9. PMID 10523062 DOI: 10.1016/S0924-977X(99)00030-9 |
0.339 |
|
| 1998 |
O'Brien M, Nutt D. Loss of consciousness and post-traumatic stress disorder. A clue to aetiology and treatment. British Journal of Psychiatry. 173: 102-104. PMID 9850219 DOI: 10.1192/Bjp.173.2.102 |
0.31 |
|
| 1998 |
Bell CJ, Nutt DJ. Serotonin and panic. The British Journal of Psychiatry : the Journal of Mental Science. 172: 465-71. PMID 9828984 DOI: 10.1192/Bjp.172.6.465 |
0.32 |
|
| 1998 |
Nutt DJ. Efficacy of mirtazapine in clinically relevant subgroups of depressed patients Depression and Anxiety. 7: 7-10. PMID 9597345 DOI: 10.1002/(Sici)1520-6394(1998)7:1+<7::Aid-Da3>3.0.Co;2-2 |
0.303 |
|
| 1997 |
Potokar J, Coupland N, Glue P, Groves S, Malizia A, Bailey J, Wilson S, Nutt D. Flumazenil in alcohol withdrawal: A double-blind placebo-controlled study Alcohol and Alcoholism. 32: 605-611. PMID 9373703 DOI: 10.1093/Oxfordjournals.Alcalc.A008302 |
0.301 |
|
| 1997 |
Wilson SJ, Lillywhite AR, Potokar JP, Bell CJ, Nutt DJ. Adult night terrors and paroxetine. Lancet (London, England). 350: 185. PMID 9250190 DOI: 10.1016/S0140-6736(05)62351-3 |
0.344 |
|
| 1997 |
Nutt D, Bell C. Practical Pharmacotherapy for Anxiety Advances in Psychiatric Treatment. 3: 79-85. DOI: 10.1192/Apt.3.2.79 |
0.346 |
|
| 1996 |
Malizia AL, Gunn RN, Wilson SJ, Waters SH, Bloomfield PM, Cunningham VJ, Nutt DJ. Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: Direct measurement of drug occupancy and effects on the human brain in vivo Neuropharmacology. 35: 1483-1491. PMID 9014164 DOI: 10.1016/S0028-3908(96)00072-X |
0.314 |
|
| 1995 |
Weinstein AM, Nutt DJ. A cognitive dysfunction in anxiety and its amelioration by effective treatment with SSRIs. Journal of Psychopharmacology (Oxford, England). 9: 83-9. PMID 22298733 DOI: 10.1177/026988119500900202 |
0.305 |
|
| 1995 |
Nutt D. The anxiety factor in depression. Journal of Psychopharmacology. 9: 185-189. PMID 22297237 DOI: 10.1177/0269881195009002031 |
0.316 |
|
| 1995 |
Malizia AL, Nutt DJ. The effects of flumazenil in neuropsychiatric disorders. Clinical Neuropharmacology. 18: 215-232. PMID 8635180 DOI: 10.1097/00002826-199506000-00002 |
0.309 |
|
| 1995 |
George DT, Nutt DJ, Rawlings RR, Phillips MJM, Eckardt MJ, Potter WZ, Linnoila M. Behavioral and endocrine responses to clomipramine in panic disorder patients with or without alcoholism. Biological Psychiatry. 37: 112-119. PMID 7718674 DOI: 10.1016/0006-3223(94)00156-W |
0.304 |
|
| 1995 |
Nutt DJ, Wilson SJ, Coupland NJ. Use of selective serotonin reuptake inhibitors and other serotonergic drugs in the biological dissection of affective disorders International Clinical Psychopharmacology. 9: 53-59. PMID 7622825 DOI: 10.1097/00004850-199501004-00008 |
0.317 |
|
| 1995 |
Malizia AL, Nutt DJ. Psychopharmacology of benzodiazepines—an update Human Psychopharmacology-Clinical and Experimental. 10. DOI: 10.1002/Hup.470100702 |
0.305 |
|
| 1994 |
Potokar J, Nutt DJ. Anxiolytic Potential of Benzodiazepine Receptor Partial Agonists Cns Drugs. 1: 305-315. DOI: 10.2165/00023210-199401040-00007 |
0.331 |
|
| 1993 |
Nutt D, Coupland N, Potokar J, Lillywhite A, Wilson S, Bailey J. Benzodiazepine receptors and panic European Neuropsychopharmacology. 3: 259-260. DOI: 10.1016/0924-977X(93)90060-Y |
0.309 |
|
| 1990 |
Nutt DJ, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Archives of General Psychiatry. 47: 917-925. PMID 2171449 DOI: 10.1001/Archpsyc.1990.01810220033004 |
0.319 |
|
| 1989 |
Gleiter CH, Nutt DJ. Chronic electroconvulsive shock and neurotransmitter receptors--an update. Life Sciences. 44: 985-1006. PMID 2564616 DOI: 10.1016/0024-3205(89)90550-X |
0.323 |
|
| 1988 |
Glue P, Nutt D. Clonidine challenge testing of alpha-2-adrenoceptor function in man: the effects of mental illness and psychotropic medication. Journal of Psychopharmacology. 2: 119-137. PMID 22156073 DOI: 10.1177/026988118800200302 |
0.304 |
|
| 1987 |
Little HJ, Nutt DJ, Taylor SC. Bidirectional effects of chronic treatment with agonists and inverse agonists at the benzodiazepine receptor. Brain Research Bulletin. 19: 371-8. PMID 2824005 DOI: 10.1016/0361-9230(87)90106-7 |
0.301 |
|
| Show low-probability matches. |